Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-14 4:08 pm Sale | 2025-09-30 | 13G | uniQure N.V. QURE | Vestal Point Capital, LP | 225,000 0.400% | -3,475,000 (-93.92%) | Filing History |
| 2025-11-14 4:07 pm Purchase | 2024-09-30 | 13G | Tenax Therapeutics, Inc. TENX | Vestal Point Capital, LP | 2,470,096 9.900% | 2,470,096 (New Position) | Filing History |
| 2025-11-14 4:06 pm Sale | 2025-09-30 | 13G | Dianthus Therapeutics, Inc. DNTH | Vestal Point Capital, LP | 1,180,000 3.000% | -2,020,000 (-63.13%) | Filing History |
| 2025-11-14 4:05 pm Purchase | 2025-09-30 | 13G | iBio, Inc. IBIO | Vestal Point Capital, LP | 4,275,000 9.900% | 4,275,000 (New Position) | Filing History |
| 2025-11-14 4:04 pm Sale | 2025-09-30 | 13G | Savara Inc. SVRA | Vestal Point Capital, LP | 4,015,000 2.300% | -6,760,000 (-62.74%) | Filing History |
| 2025-11-14 4:03 pm Sale | 2025-09-30 | 13G | KalVista Pharmaceuticals, Inc. KALV | Vestal Point Capital, LP | 750,000 1.500% | -3,250,000 (-81.25%) | Filing History |
| 2025-11-14 4:02 pm Sale | 2025-09-30 | 13G | Tyra Biosciences, Inc. TYRA | Vestal Point Capital, LP | 2,425,000 4.500% | -454,829 (-15.79%) | Filing History |
| 2025-11-14 4:02 pm Purchase | 2025-09-30 | 13G | Astria Therapeutics, Inc. ATXS | Vestal Point Capital, LP | 4,956,000 8.800% | 956,000 (+23.90%) | Filing History |
| 2025-11-14 4:00 pm Purchase | 2025-09-30 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Vestal Point Capital, LP | 4,117,302 7.500% | 889,141 (+27.54%) | Filing History |
| 2025-08-14 4:03 pm Sale | 2025-06-30 | 13G | uniQure N.V. QURE | Vestal Point Capital, LP | 3,700,000 6.800% | -1,092,572 (-22.80%) | Filing History |
| 2025-08-14 4:00 pm Sale | 2025-06-30 | 13G | Nyxoah S.A. NYXH | Vestal Point Capital, LP | 1,402,002 3.700% | -916,952 (-39.54%) | Filing History |
| 2025-08-14 3:57 pm Purchase | 2025-06-30 | 13G | Bicara Therapeutics Inc. Common Stock BCAX | Vestal Point Capital, LP | 5,000,000 9.200% | 2,231,025 (+80.57%) | Filing History |
| 2025-08-14 3:51 pm Purchase | 2025-06-30 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Vestal Point Capital, LP | 3,228,161 6.000% | 3,228,161 (New Position) | Filing History |
| 2025-08-14 3:47 pm Purchase | 2025-06-30 | 13G | Dianthus Therapeutics, Inc. DNTH | Vestal Point Capital, LP | 3,200,000 9.950% | 1,499,931 (+88.23%) | Filing History |
| 2025-05-15 4:14 pm Purchase | 2025-03-31 | 13G | Tyra Biosciences, Inc. TYRA | Vestal Point Capital, LP | 2,879,829 5.400% | 2,879,829 (New Position) | Filing History |
| 2025-05-15 4:14 pm Purchase | 2025-03-31 | 13G | Dianthus Therapeutics, Inc. DNTH | Vestal Point Capital, LP | 1,700,069 5.300% | 1,700,069 (New Position) | Filing History |
| 2025-05-15 4:13 pm Purchase | 2025-03-31 | 13G | Bicara Therapeutics Inc. Common Stock BCAX | Vestal Point Capital, LP | 2,768,975 5.100% | 2,768,975 (New Position) | Filing History |
| 2025-05-15 4:13 pm Purchase | 2025-03-31 | 13G | uniQure N.V. QURE | Vestal Point Capital, LP | 4,792,572 8.900% | 1,767,572 (+58.43%) | Filing History |
| 2025-05-15 4:12 pm Sale | 2025-03-31 | 13G | Solid Biosciences Inc. SLDB | Vestal Point Capital, LP | 1,753,558 2.300% | -1,046,442 (-37.37%) | Filing History |
| 2025-05-15 4:11 pm Sale | 2025-03-31 | 13G | Nyxoah S.A. NYXH | Vestal Point Capital, LP | 2,318,954 6.200% | -605,262 (-20.70%) | Filing History |